<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Argatroban</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00278</strong>&#160; (APRD00105)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (<span class="caps">ACC</span>) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (<span class="caps">HIT</span>) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with <span class="caps">HIT</span> and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00278/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00278/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00278.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00278.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00278.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00278.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00278.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00278">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>74863-84-6</td></tr><tr><th>Weight</th><td>Average: 508.634<br>Monoisotopic: 508.246788982</td></tr><tr><th>Chemical Formula</th><td>C<sub>23</sub>H<sub>36</sub>N<sub>6</sub>O<sub>5</sub>S</td></tr><tr><th>InChI Key</th><td>KXNPVXPOPUZYGB-XYVMCAHJSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H36N6O5S/c1-14-8-10-29(18(12-14)22(31)32)21(30)17(6-4-9-26-23(24)25)28-35(33,34)19-7-3-5-16-11-15(2)13-27-20(16)19/h3,5,7,14-15,17-18,27-28H,4,6,8-13H2,1-2H3,(H,31,32)(H4,24,25,26)/t14-,15-,17+,18-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2R,4R)-1-[(2S)-5-[(diaminomethylidene)amino]-2-[(3R)-3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido]pentanoyl]-4-methylpiperidine-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td>Alpha Amino Acid Amides; Benzenesulfonamides; Hydroquinolines; N-Acylpiperidines; Piperidinecarboxylic Acids; Sulfonyls; Tertiary Carboxylic Acid Amides; Sulfonamides; Guanidines; Tertiary Amines; Carboxylic Acids; Enolates; Polyamines; Amidines; Secondary Amines</td></tr><tr><th>Substituents</th><td>alpha-amino acid amide; benzenesulfonamide; alpha-amino acid or derivative; tetrahydroquinoline; piperidinecarboxylic acid; n-acyl-piperidine; benzene; piperidine; sulfonyl; tertiary carboxylic acid amide; sulfonamide; sulfonic acid derivative; carboxamide group; guanidine; tertiary amine; secondary amine; carboxylic acid; polyamine; amidine; enolate; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Argatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.</td></tr><tr><th>Pharmacodynamics</th><td>Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. Argatroban does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation. Argatroban is highly selective for thrombin with an inhibitory constant (K<sub>i</sub>) of 0.04 &#181;M. At therapeutic concentrations, Argatroban has little or no effect on related serine proteases (trypsin, factor Xa, plasmin, and kallikrein).
Argatroban is capable of inhibiting the action of both free and clot-associated thrombin.</td></tr><tr><th>Mechanism of action</th><td>Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.</td></tr><tr><th>Absorption</th><td>Bioavailability is 100% (intravenous).</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>174 mL/kg</li>
	<li>12.18 L [70-kg adult]</li>
</ul></td></tr><tr><th>Protein binding</th><td>54%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Liver via hydroxylation and aromatization of the 3-methyltetrahydroquinoline ring. Age and gender do not substantially affect the pharmacodynamic or pharmacokinetic profile of argatroban.</p></td></tr><tr><th>Route of elimination</th><td>Argatroban is excreted primarily in the feces (65%), presumably through biliary secretion; 22% is eliminated via urine.</td></tr><tr><th>Half life</th><td>39 and 51 minutes</td></tr><tr><th>Clearance</th><td><ul>
	<li>5.1 L/kg/hr [infusion doses up to 40&#160;mcg/kg/min]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Excessive bleeding</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Argatroban Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.6195</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8933</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7293</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8193</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6701</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6802</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8147</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.5571</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8861</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5477</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8849</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.662</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8789</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7706</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8316</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9636</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6238
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7551
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9966
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.5767 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9833
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6071
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pfizer inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intravenous</td><td>100mg/mL</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Herbs and food with anticoagulant/antiplatelet activity. Major interactions may occur with danshen, dong quai, evening primrose oil, gingko, policosanol, willow bark</li></ul></td></tr></tbody></table>